AUSTIN, Texas--(BUSINESS WIRE)--Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today issued a follow-up statement to an announcement on Monday, April 27, 2009, confirming that the xTAG® Respiratory Viral Panel (RVP) assay has been demonstrated to be effective in surveillance of swine flu. Specifically, Luminex has verified through testing on confirmed swine flu-positive samples that the xTAG RVP assay will correctly identify these samples as positive for influenza A and negative for common seasonal flu strains of influenza A H1 and H3. This is the expected outcome for novel influenza A strains which prompts follow-up testing by state or federal public health labs with assays such as the Centers for Disease Control (CDC) swine flu assay.
